HIV replication inhibiting pyrimidines

Details for Australian Patent Application No. 2011200708 (hide)

International Classifications

Event Publications

10 March 2011 Application Open to Public Inspection

Published as AU-A-2011200708

10 March 2011 Complete Application Filed

Priority application(s): 60/143,962 15.07.99 US; 60/107,792 10.11.98 US

2 June 2011 Standard Patent Sealed

16 June 2011 Extension of Term of Standard Patents

Janssen Pharmaceutica N.V. The earliest first regulatory approval date provided by the patentee 19 Dec 2008 For the goods INTELENCE etravirine

28 July 2011 Extension of Term of Standard Patents

Janssen Pharmaceutica N.V. The earliest first regulatory approval date provided by the patentee 19 Dec 2008 For the goods INTELENCE etravirine Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

12 January 2012 Extension granted

Janssen Pharmaceutica N.V. The earliest first regulatory approval date provided by the patentee 19 Dec 2008 For the goods INTELENCE etravirine Extension of Term of patent pursuant to Section 77 expires on 24 Sep 2023

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.